Biohit Oyj

BIOBV.HE maintains a strong liquidity position, with a current ratio of 2.56, indicating the company can cover its short-term liabilities more than twice over. The company's liquidity_fpt score is high, supported by EUR 3.54 million in cash and equivalents, which is a significant portion of its total assets of EUR 19.81 million. However, the company reported negative operating cash flow of EUR -0.75 million, which may signal short-term operational challenges.

In terms of profitability, BIOBV.HE demonstrates a return on equity (ROE) of 18.33% and a return on assets (ROA) of 13.83%, both of which are strong indicators of efficient capital use and asset management. The company's operating income of EUR 2.92 million and net income of EUR 2.74 million reflect solid earnings performance. These metrics are well above the industry median for ROE and ROA, suggesting that the company is outperforming its peers in terms of profitability.

Geographically and segment-wise, the company's exposure is not explicitly detailed in the available data. However, the revenue concentration is not specified, and no major segments are disclosed. This lack of detail may limit the ability to assess the company's exposure to specific markets or product lines.

The company's growth trajectory appears stable, with no significant changes in revenue or earnings reported in the latest financial data. The outlook for the current fiscal year does not indicate a substantial increase or decrease in revenue, and the next fiscal year is expected to follow a similar trend. The absence of a clear growth driver or decline factor suggests a relatively flat performance horizon.

Risk factors for BIOBV.HE are currently low, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio of 0.11 indicates a conservative capital structure, with minimal long-term debt of EUR 1.59 million relative to its total equity of EUR 14.94 million. The dilution potential is also low, with no significant dilution sources identified in the latest filings.

Recent events and filings do not show any material changes in the company's operations or financial position. The company's free cash flow of EUR 2.54 million and capital expenditure of EUR -0.62 million suggest that it is generating sufficient cash to support its operations and reinvestment needs. Analysts have provided a mean price target of EUR 3.50, with a median recommendation of 2.00, indicating a generally positive outlook.